Arcutis Biotherapeutics (ARQT) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Arcutis Biotherapeutics (ARQT) is Neutral.

The composite score behind that read is +0.06, weighing +0.11 of bullish evidence against -0.26 bearish.

Arcutis Biotherapeutics last closed at $26.58, +8.53% on the session.

Against the IVW growth benchmark the position is +7.73% over the forecast window.

The read is built from 15 underlying insights — 9 bullish and 6 bearish.

Agreement across those insights is 40%.

2 graded predictions for ARQT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Arcutis Biotherapeutics in the 5th percentile on valuation and the 73rd percentile on return on equity, where 100 is best.

Arcutis Biotherapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $3.08B.

StockMap tracks Arcutis Biotherapeutics as the 68th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Arcutis Biotherapeutics ranks 57th of 381 in the group, against a group median of -0.08.